CHI3L1 and frontotemporal dementia: Previous FTD biomarker discovery studies using unbiased mass spectrometry (MS)-based technologies identified multiple biomarker candidates (e.g., YKL-40 in FTD and NPTXR in GRN mutation carriers) [30, 31].